drugset
drugset / Trial / NCT03903081

The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects

NCT03903081 ↗

Phase 1 Completed 93 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single \& Multiple Ascending Dose Study to Access the Tolerability and Pharmacokinetics of HEC110114 Tablets in Healthy Adult Subjects

Timeline

Start
2019-03-06
Primary completion
2019-10-29
Completion
2019-10-29

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC110114 Unknown 100 mg Oral
Subject HEC110114 Unknown 300 mg Oral
Subject HEC110114 Unknown 600 mg Oral
Subject HEC110114 Unknown 800 mg Oral
Subject HEC110114 Unknown 1000 mg Oral
Subject HEC110114 Unknown 1200 mg Oral
Subject HEC110114 Unknown 1600 mg Oral

Indications

chronic hepatitis C virus infection